Back to All Events

Best of Lung

Hybrid Event | TBD CE/CME Credits & MOC Points

We invite you to join us for the Best of Lung Cancer Conference. This innovative and state-of-the-art program will feature some of the world's leading lung cancer experts to present the latest research and strategies for the care of lung cancers — incorporating data from the major oncologic annual meetings.

 
 

Conference Agenda
Saturday, September 20, 2025

8:00 AM
Coffee and Exhibits

8:30 AM
Special Session

8:42 AM
KRAS G12C-Mutated NSCLC: Evolving Treatment Strategies

8:54 AM
Targeted Therapies in Lung Cancer: Current and Emerging Options

9:06 AM
Immunotherapy in Lung Cancer: Expanding Indications and Future Directions

9:18 AM
Breakfast and Exhibits

9:33 AM
Non-CME Presentation

10:18 AM
Comprehensive Diagnostics in Lung Cancer: Integrating Genomics and Liquid Biopsies

10:30 AM
Lung Cancer Screening: Updates and Best Practices

10:42 AM
Locally Advanced NSCLC: Multidisciplinary Management Strategies

10:54 AM
Small Cell Lung Cancer: Advances in Immunotherapy

11:06 AM
Managing Metastatic Lung Cancer: New Therapies and Approaches

11:18 AM
Lunch and Exhibits

11:33 AM
Non-CME Presentation

12:18 PM
Emerging Biomarkers and Their Role in Personalizing Lung Cancer Treatment

12:30 PM
Managing Treatment-Related Toxicities in Lung Cancer

12:42 PM
Addressing Health Disparities in Lung Cancer Care

12:54 PM
Break and Exhibits

1:04 PM
Extended Panel Discussion: Integrating New Therapies into Lung Cancer Practice

3:30 PM
Adjourn

Agenda Subject To Change. All times are EST.

 
    • Apply the current standards of oncology care and key updates from national clinical guidance pathways to optimize the management of patients with lung cancer.

    • Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with lung cancer.

    • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with lung cancer.

  • In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Nurses (ANCC) Credit Designation

    Amedco LLC designates this activity for a maximum of TBD ANCC contact hours.

    Physicians (ACCME) Credit Designation

    Amedco LLC designates this live activity for a maximum of TBD AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

    Amedco LLC designates this activity for a maximum of TBD knowledge-based CPE contact hours.

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

    American Board of Internal Medicine (ABIM) MOC Credit

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to TBD Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.

    • Free registration for all healthcare providers

    • Expert sessions that present the most clinically relevant data, research, and clinical strategies

    • Real-time discussion and debate

    • Networking with peers, colleagues, and medical professionals

    • Access to the latest industry information and resources

 
Previous
Previous
September 9

Cancer Updates GU and Heme

Next
Next
September 25

Cancer Updates GU and Lung